cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Incyte Corporation
19 own
14 watching
Current Price
$75.92
$1
(1.33%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
12,642.13M
52-Week High
52-Week High
83.95000
52-Week Low
52-Week Low
50.35000
Average Volume
Average Volume
1.32M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
36.3859
iconMarket Capitalization12,642.13M
icon52-Week High83.95000
icon52-Week Low50.35000
iconAverage Volume1.32M
iconDividend Yield--
iconP/E Ratio36.3859
What does the Incyte Corporation do?
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.
Read More
How much money does Incyte Corporation make?
News & Events about Incyte Corporation.
Globe Newswire
1 year ago
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (Incyte or the Company) (NASDAQ:INCY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation ...
Business Wire
1 year ago
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has granted a marketing authorization for Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Opzelura is the first and only...
Globe Newswire
1 year ago
NEW YORK, April 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (Incyte or the Company) (NASDAQ:INCY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation ...
Business Wire
1 year ago
Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of myeloid/lymphoid neoplasms (MLNs) with FGFR1 fusion (also known as 8p11...
Business Wire
1 year ago
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV...
Frequently Asked Questions
Frequently Asked Questions
What is Incyte Corporation share price today?
plus_minus_icon
Can Indians buy Incyte Corporation shares?
plus_minus_icon
How can I buy Incyte Corporation shares from India?
plus_minus_icon
Can Fractional shares of Incyte Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Incyte Corporation stocks?
plus_minus_icon
What is today’s traded volume of Incyte Corporation?
plus_minus_icon
What is today’s market capitalisation of Incyte Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Incyte Corporation?
plus_minus_icon
What percentage is Incyte Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Incyte Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$75.92
$1
(1.33%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
AxoGen, Inc.
AxoGen, Inc.
$14.91
$0.24 (1.64 %)
Fate Therapeutics Inc
Fate Therapeutics Inc
$2.65
$0.27 (11.34 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$325.50
$3.14 (0.97 %)
Bio-Techne Corp.
Bio-Techne Corp.
$74.51
$0.62 (0.84 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
AxoGen, Inc.
AxoGen, Inc.
$14.91
$0.24 (1.64 %)
Fate Therapeutics Inc
Fate Therapeutics Inc
$2.65
$0.27 (11.34 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$325.50
$3.14 (0.97 %)
Bio-Techne Corp.
Bio-Techne Corp.
$74.51
$0.62 (0.84 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00